Elucid CEO: AI Must Change Cardiac Decisions, Not Just Speed Them
United States – October 17, 2026 -- Nearly half of all heart attacks occur in patients classified as low risk under traditional factors such as age, cholesterol and family history, Elucid CEO Kelly Huang said in AdvaMed's "Insight Series: AI & Digital Health," arguing that AI must change clinical decisions rather than accelerate existing ones.
Elucid extracts plaque biology and blood-flow data from a single CT scan
Elucid's Plaque-IQ software analyzes an existing coronary CT angiogram to quantify plaque type and amount in coronary and carotid vessels. Its BioIntegrated FFR-CT predicts fractional flow reserve values along each vessel, using invasive FFR as ground truth. Plaque algorithms are validated against histology.
Huang said two patients can show identical plaque volume and similar stenosis yet carry different risk: one has lipid-rich, unstable plaque, the other calcified, stable plaque.